Targeting prion protein interactions in cancer - BV FAPESP
Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Targeting prion protein interactions in cancer

Full text
Author(s):
Santos, Tiago G. [1, 2, 3] ; Lopes, Marilene H. [2, 3, 4] ; Martins, Vilma R. [1, 2, 3]
Total Authors: 3
Affiliation:
[1] AC Camargo Canc Ctr, Int Res Ctr, Sao Paulo - Brazil
[2] Natl Inst Translat Neurosci, Sao Paulo - Brazil
[3] Natl Inst Oncogen CNPq MCT FAPESP, Sao Paulo - Brazil
[4] Univ Sao Paulo, Inst Biomed Sci, Dept Cell & Dev Biol, Sao Paulo - Brazil
Total Affiliations: 4
Document type: Journal article
Source: PRION; v. 9, n. 3, p. 165-173, MAY 4 2015.
Web of Science Citations: 14
Abstract

In recent years, prion protein (PrPC) has been considered as a promising target molecule for cancer therapies, due its direct or indirect participation in tumor growth, metastasis, and resistance to cell death induced by chemotherapy. PrPC functions as a scaffold protein, forming multiprotein complexes on the plasma membrane, which elicits distinct signaling pathways involved in diverse biological phenomena and could be modulated depending on the cell type, complex composition, and organization. In addition, PrPC and its partners participate in self-renewal of embryonic, tissue-specific stem cells and cancer stem cells, which are suggested to be responsible for the origin, maintenance, relapse, and dissemination of tumors. Interference with protein-protein interaction has been recognized as an important therapeutic strategy in cancer; indeed, the possible interference in PrPC engagement with specific partners is a novel strategy. Recently, our group successfully used that approach to interfere with the interaction between PrPC and HSP-90/70 organizing protein (HOP, also known as stress-inducible protein 1 - STI1) to control the growth of human glioblastoma in animal models. Thus, PrPC-organized multicomplexes have emerged as feasible candidates for anti-tumor therapy, warranting further exploration. (AU)

FAPESP's process: 11/13906-2 - Contribution of the co-chaperone STI1 in mouse development: embryonic stem cell as approach
Grantee:Marilene Hohmuth Lopes
Support Opportunities: Research Grants - Young Investigators Grants
FAPESP's process: 09/14027-2 - Mechanisms associated with the function of prion protein and its ligand STI1/Hop: therapeutic approaches
Grantee:Vilma Regina Martins
Support Opportunities: Research Projects - Thematic Grants